Q4 2022 Catalent Inc Earnings Call
Measures.
Please also refer to Catlin Form 10-K that will be filed with the SEC today for additional information on the risks and uncertainties that may bear on our operating results performance and financial condition.
Now I would like to turn the call over to Alessandro Maselli Who's opening remarks will begin on slide six of the presentation.
Thanks, Paul and welcome everyone to the call.
<unk> 22 was another extraordinary year for covenant during the year, we achieved the strong results both financially and operationally, but also making a positive impact on our global community by that EBIT and got a mission to develop and deliver products that help people leave a better and healthier lives somewhat top highlights since.
July 21 include debt significantly investing in capacity and infrastructure in both North America, and Europe , particularly focused on servicing to high demand segments of the market.
Another growth engine for the company through our entry in consumer preferred dosage gummy dosage forms so for nutritional supplements, which we continue to aggressively expand.
Agreeing to acquire a new capacity that will accelerate our ability to handle demand in the attractive category of IV both in compounds.
Expanding and deepening our one of our best starting tools in the industry.
Intensifying, our long standing commitment to sustainability accelerating our growth strategy and delivering record financial results, despite the difficult inflationary environment and ongoing supply chain challenges.
<unk> 22, net revenue was up four points to $83 billion, which grew organically in constant currency to 20% compared to prior fiscal year.
This growth was primarily driven by broad demand for our biologics offering including the demand for COVID-19 related programs.
Demand for our customer prescription products and a rebound in demand for our consumer products.
Adjusted EBITDA for the year was $1 $29 billion, reflecting constant currency organic growth of 28% compared to fiscal 'twenty one.
We also increased adjusted EBITDA margin to 26, 6% up 110 basis points from 25, 5% we recorded in fiscal 'twenty one.
Fiscal 'twenty to adjusted net income was $694 million.
Our $3 84 per diluted share up from $3 <unk> per diluted share in fiscal 'twenty one.
Now focusing on the fourth quarter I am pleased to report that we have closed out the year with strong results is our robust business momentum more than offsets Edwards from inflation and a favorable exchange transition translation.
As shown on slide seven our fourth quarter revenue was $1 30.
$31 billion, increasing 10% as reported or 15% in constant currency compared to the fourth quarter of fiscal 'twenty, one when excluding acquisition and divestitures organic growth was 10% immediately in constant currency. This growth was primarily driven by added biologics segment, which grew double digits. Despite low.
Year on year revenue in the quarter from COVID-19 programs.
Our fourth quarter, adjusted EBITDA was $384 million increased 10% as reported or 16% on a constant currency basis compared to the fourth quarter of fiscal 'twenty, one when excluding acquisition and divestiture organic growth was 15% measured in constant currency.
Our adjusted net income for the fourth quarter was at $150 million or $1 19 per diluted share up from $1 16.
The cents per diluted share in the corresponding prior year period.
As you know we put in place in the organizational structure effective July 1st the start to our fiscal 2003, which was also the same day transition to my current role as the CEO of our new structure will look positive better manage the business.
It has grown over the last few years, while also enabling a value creation by giving our customers easier access to a broader array of services to the <unk>.
Organizationally has reduced our number of operating segments from four to two with one focusing on biologics and the other on pharmaceuticals and consumer health.
Each segment represents roughly.
Out of the total company revenues illustrated on slide eight we will begin reporting our results under this new structure, starting with our first quarter earnings call in early November and we will also issue a statement of recent historical results under the new structure in the coming weeks.
The new pharma and consumer Health segment includes the offsetting over three of our prior segments Softgel and all that technology oral and specialty delivery and clinical supply services and overwhelmingly serves a small molecule programs.
Notable offerings in pharma and consumer health segment includes our market leading capabilities for complex oral solid softgel formulation <unk> fastly soft tablets gummy sense of choose and clinical development entitled supply services.
We've established dedicated teams focus individually on pharmaceutical consumer health and clinical development and supply offerings. Our long term net revenue growth expectation for the pharma and consumer health segment. These are 6% to 10%, which should be which is a 200 basis points higher at the upper end than the <unk>.
Combined with growth rates of the three previous segments, not including that within this new segment.
This is due to the commercial synergies unlocked by our new go to market strategy enabled by these organizational structure and greater exposure to higher growth sectors. So small molecule market as a result of recent investments and acquisitions.
The new biologic segment is essentially the same as.
As the biologic segment, we reported in fiscal 'twenty, two with some internal organization adjustment that we could better service the newer modalities employed by many of our Biopharma customers.
Our expected long term growth net revenue growth rate for the biologics segment remains at the 10% to 15%.
There are a set of a benefit to this important important structural change first the simplify the reporting structure enable us to be more agile in meeting and anticipating customer needs and expectations as well as adapting to evolving customer they need to see rents second creating a more integrated offering to make it easier to count for custom.
But to do business with government moving leading to an enhanced customer experience and minimize barriers for existing and potential customers success multiple set to be submitted by enabling our commercial synergies.
Finally, it allows us for even greater operational excellence as a result, our quality and operations oversight that bolsters accountability across the network importantly, based on our confidence in the long term growth expected across both segments to our continued investment in synergy, resulting from our reorganization we are in a car.
For the full position to raise the top end of our projected consolidated the long term growth rate to 12% compared to the previous 10 percentage is as shown in slide eight.
Looking to fiscal 'twenty three while Tom will review the details of our guidance guidance later in the call I would like to make some high level remarks on our revenue outlook.
I indicated on our last earnings call in May that we were comfortable projecting fiscal 'twenty three organic growth in line with our previous long term organic revenue growth.
Rate of 8% to temper spent despite our forecast for a considerable decline in revenue from COVID-19 related programs.
Stan.
Given the more pronounced seasonality, we projected customer ordering the for these programs as well as the phasing of our fiscal year. We have further dd's did the level of coffee related related to revenue in our guidance model.
The new model used for the guidance. We are sharing today takes into account that the updated timing of the switch to single dose hormones and forecast a roughly two thirds decrease in call. It the vaccine related volumes in fiscal 2003 compared to fiscal 2002.
After accounting for these additional DD skin Gulf coffee revenue, we still expect our fiscal 2003 organic growth at the midpoint to be around the low.
And our long term range on a constant currency basis.
Our projects on a fiscal 'twenty three revenue growth is driven by our non COVID-19 business, which is expected to grow organically by more than 25% at constant currency due to several factors including.
Growth expansions of existing assets that came online in the past year, such as our new acceptance lines in medicine, and <unk> product lines in Bloomington in Europe .
Maximizing efficiencies in other areas of our global network, including that those that manufactured our gummy format, and previously announced build out our cell therapy, and <unk> offerings to Europe and U S.
Adding the new capacity in the next two quarters, including the opening of eight the previously announced that gene therapy suites in BWI.
Additional tax substance capacity in Bloomington.
The large commercial tech transfer programs in our DUC product assets, we discussed on our last earnings call and later in fiscal 'twenty three our two new facility currently completing construction our commercial cell therapy facility increased and our drug substance facility Knoxville stature in that eight to generate meaningful revenue.
Additional growth not reflected in the fiscal 'twenty three guidance. We're issuing today is anticipated following the closing of our recently announced agreement to acquire a metrics contract services are full service specialty CMO, We've got 330000 square foot facility in Greenville, North Carolina for 400.
$75 million for Mayne pharma is summarized on slide nine.
The acquisition of this business and facility, which has enjoyed that well over $100 million in capital improvements in the last five years will enable katherine proximity to existing plants to meet the increasing demand for fit for scale high potent Dr. Manifested of course, the acquisition remains subject to customary closing.
<unk>, including antitrust.
<unk>, we expect to close the acquisition before December 31st.
One reason for our enthusiasm about the medical business is the growth in the number of potent compounds in BRL saw its market driven by strong growth in the oral oncology pipeline, where more than 80% of programs to be quite potent handling as well as the industry shifts to <unk> discovery, which often yields more potent less solid.
<unk> molecules.
In the last several years other than <unk> seen in numerous opportunities to work with a highly potent compounds, which we can now service. After we completed the acquisition of metrics.
Medics Greeneville facility generated revenue of more than $90 million during our fiscal 'twenty two from services from third party customers.
<unk> large pharma and emerging biotech customers as well as the manufacturing services for several mayne pharma on products.
Note that our deal with the Mayne pharma includes a long term supply agreement to manufacture certain of its product at the Greenville facility. After closing once acquired domestic business will become part of our pharma and consumer health segment and is expected to deliver revenue growth compatible to the segments project.
The overall long term growth of 6% to 10%.
<unk> EBITDA margin is accretive.
So the PCH margin and we intend to drive this margin above 30% over time by increasing utilization.
Auditing department handling capabilities in FIFA scale capacity capacity through metrics represent a continuation of our strategy to maintain a balanced portfolio offerings that closely matches the little industry pipeline, which includes a growing number of innovative small molecules that are complex to formulate or requires specialized handling.
One innovation in the biologics market is more frequently mention India deadlines oral delivery is still the foundation of the prescription drug pipeline with almost 6000 oral compounds currently in development.
Approximately 10% from last year and Thats been the focus of recent substantial pharma M&A activities.
The combination of strategic acquisitions, like <unk>, and our organic investments Exposition, our overall portfolio for long term success, including being in a strong position to meet our long term targets.
As I wrap up my remarks. This morning, let me add the goals and objectives for fiscal two entities at the <unk> and the rest of the executive team laid the foundation for executing on long term start on our long term strategy and also help to position us to deliver another strong fiscal year as we navigate the obstacles facing our industry today, which.
Include the continuing to supply continuing supply chain challenges inflationary pressures.
And as you supply issues in Europe , the uncertainty in the biotech funding, a lower and more seasonable demand.
For vaccine as we exit the pandemic.
I am energized by our strategical growth ambitions the roadmap that we have in place and the cognitive working together to deliver for patients who rely on US we continue to be in a strong position to succeed in the attractive markets we serve.
Finally, I would like to congratulate current fleet was elected by our board of directors last week to become into both the newest member effective September 15.
<unk> recently retired after a long and distinguished career in the pharmacy B C. Industry. We then most recent role as covenants senior Vice President and Chief Commercial Officer, and we are delighted to be able to continue current involvement with the company now I would like to turn the call over to Tom.
Thanks, Alessandra I'll begin this morning with a discussion on segment performance, where commentary around segment growth will be in constant currency.
I'll start on slide 10, with the biologics segment.
Biologics net revenue in Q4 of $667 million increased 14% compared to the fourth quarter of 2021.
Our strong net revenue growth was driven organically by increased demand in our cell and gene therapy drug product and drug substance offerings, which more than offset lower year over year revenue from our COVID-19 related progress our fiscal 2022 third quarter marked the peak and our COVID-19 related revenue.
Q4 down both sequentially and year over year.
When looking at the bar graph on Slide 10, you will see that biologics commercial revenue declined year on year.
The driver of the year over year decline is the conclusion of our COVID-19 program that was classified as a commercial product for revenue recognition purposes. This program is not expected to generate future revenue.
The segment EBITDA margin of 32, 8% was up more than 210 basis points year over year from the 39% recorded in the fourth quarter of fiscal 2021, and up 170 basis points sequentially over the third quarter.
Year over year margin expansion was fueled by strong operational efficiencies, which more than offset the impact of remediation activity in Brussels.
That remediation related costs were lower in Q4 than in Q3 and remediation activity continues at the site in fiscal 2023.
In addition margin was aided by a mix shift away from lower margin component sourcing revenue, which as mentioned on past calls represents approximately 25% of total COVID-19 vaccine revenue.
As COVID-19 revenue continues to decline so will the related dilutive margins from component sourcing that we have recently experienced.
As shown on slide 11, Softgel and oral technologies net revenue was $350 million increased 22% compared to the fourth quarter of fiscal 2021 with segment EBITDA, increasing 9% over the same period last fiscal year.
The October one 2021 acquisition of the Terra contributed 18 percentage points to <unk> net revenue growth and 13 percentage points to the segment's EBITDA growth during the quarter.
The operational performance of the acquired <unk> business continues to exceed our expectations and remains an important driver for continued margin expansion for the company.
SRT organic net revenue increased 4% and was driven by continued growth and development revenue as well as demand for both prescription products and consumer health products, However, supply chain challenges inflationary pressures and unfavorable mix weighed on overall organic results, yielding the impact of <unk>.
<unk> product demand.
Slide 12 shows the results of the oral and specialty delivery segment net revenue grew 11% and segment EBITDA was up 27% over the fourth quarter of last year.
Overall demand for our <unk> offerings reached a record level fueling significant growth.
This strong demand was further supplemented by revenue from our royalty agreement related to our <unk> platform, which was the primary driver of the segment's strong EBITDA margin.
As shown on slide 13, our clinical supply services segment posted net revenue of $104 million.
Representing 4% growth over the fourth quarter of fiscal 2021, driven by growth in our storage and distribution services.
<unk> EBITDA declined 2% driven by unfavorable mix.
As of June 32022 backlog for the segment was $540 million up from $529 million at the end of last quarter and up 10% from June 32021.
The segment recorded net new business wins of $132 million during the fourth quarter compared to $119 million in the fourth quarter of the prior year.
The segment's trailing 12 month book to Bill ratio is one one times.
Moving to our consolidated adjusted EBITDA on Slide 14, our fourth quarter, adjusted EBITDA increased 10% to $384 million or 29, 2% of net revenue, which was roughly in line with the fourth quarter of fiscal 2021.
On a constant currency basis, our fourth quarter, adjusted EBITDA increased 16% compared to the fourth quarter of the prior year.
For the full year, adjusted EBITDA increased 26% to $1 two $9 billion over fiscal 'twenty, one and 'twenty, 2008% on a constant currency basis.
Adjusted EBITDA margin increased 110 basis points to 26, 6% in fiscal 'twenty two from 25, 5% in fiscal 'twenty one.
As shown on slide 15 fourth quarter, adjusted net income was $215 million or $1 19 per diluted share compared to adjusted net income of $209 million or $1 16 per diluted share in the fourth quarter a year ago.
For the full fiscal year adjusted net income was $694 million.
$3 84 per diluted share compared to adjusted net income of $549 million or $3 <unk> per diluted share in fiscal 'twenty one.
Slide 16 shows our debt related ratios and our capital allocation priorities.
Catalyst net leverage ratio as of June 32022 was two nine times slightly below our long term target of three nine times. This compares to net leverage of two six times on March 31, 2022, and two two times on June 32021.
A combination.
Our combined balance of cash cash equivalents in marketable securities as of June 32022 was $538 million.
Two $880 million as of March 31, 2022.
Note that our free cash flow has been negatively impacted the last two years by our strategic decision at the onset of the pandemic to increase inventory levels, which continue to allow us to have the inputs, we need to meet our supply obligations to our customers and their patients in a timely manner.
When we feel the time is appropriate and are more comfortable with the stabilization of our supply chain. We will begin to reverse course, which will have a future positive effect on free cash flow.
Similarly, the realization of contract assets will also drive a favorable impact on future free cash flow after negatively impacting our fiscal 2022 results as.
As of June 32022, our contract asset balance was $441 million, an increase of $260 million compared to June 32021.
The overwhelming majority of this increase is related to some notably large development programs such as for some of the Covid vaccines, where revenue is recorded based on our percentage of completion.
Versus entirely on batch release as it is for commercial programs. This difference in approach effects. When we are able to invoice customers, thereby delaying cash realization and negatively affecting free cash flow.
Moving on to capital expenditures, we added a new slide in the appendix to illustrate our annual Capex spend.
In fiscal 'twenty, two capex as a percentage of revenue was 14% compared to 17% in fiscal 'twenty one.
Capex as a percent of revenue was a bit lower than we had initially expected for fiscal 'twenty, two driven by higher than expected revenue growth as well as some supply chain related delays and longer lead times than initially anticipated for some of our capital projects for fiscal 'twenty three we expect capex.
Next to be in a similar range as fiscal 'twenty, two or approximately 13% to 15% of net revenue.
Now, we turn to our financial outlook for fiscal 2023 as outlined on slide 17 the.
The midpoint is reflected in our outlook assumed the challenging macro environment remains stable.
We expect full year net revenue in the range of $4 97, 5 billion to five $2 billion to $5 billion representing.
Representing growth of three 8% on an as reported basis compared to fiscal 2022.
Current FX rates, which we use in this forecast are forecasted to have a negative impact of approximately three to four percentage points on our revenue and adjusted EBITDA growth.
We project that inorganic revenue, which basically reflects one remaining quarter of the Terra acquisition until the first anniversary of that acquisition on October one will positively impact our annual growth rate by less than one percentage point.
So after taking into account. These two considerations are expected organic constant currency net revenue growth rate in fiscal 'twenty three is approximately 8% at the midpoint of our guidance range.
The acquisition of metrics will be factored into updated guidance, we will share during the first earnings call. Following the close of the transaction.
For full year adjusted EBITDA, we expect a range of $1 31 to $1 39 billion representing growth of 228% at reported rates compared to fiscal 2022.
I would like to remind you of the seasonal nature of our business, where revenue and EBITDA generation is historically more weighted to the back half of the year with roughly 60% of fiscal 2023, adjusted EBITDA expected to be generated in the second half of the year.
Now, we expect limited EBITDA margin this year on a constant currency basis, while we're still on track to achieve our fiscal 2026 EBITDA margin target of 30%. There are a number of factors impacting margin expansion in fiscal 'twenty, three including headwinds from Covid related volume declines.
We have been anticipating.
Inflationary and supply chain pressures.
Startup costs related to our acquisitions of Princeton in Oxford, which we're absorbing in our organic assumptions because neither asset generated substantial revenue prior to its acquisition and foreign exchange translations as our margin profile is higher outside of the U S. While the majority of our corporate costs are domestic.
Note that swings in the euro have a greater impact on FX translation, then the pound.
Moving to adjusted net income, we expect full year <unk> of $660 million to $730 million, representing a range from a decline of 5% to an increase of 5% compared to fiscal 2022. However was.
It was negatively impacted by FX translation of more than four percentage points.
In addition, anr growth in fiscal 'twenty, three is being impacted by all of the items affecting adjusted EBITDA as well as the following items first an expected higher effective tax rate in the 24% to 25% range compared to 23, 4% in fiscal 2022 given the.
Year on year increase in the waiting of earnings in higher tax jurisdictions.
An increase in interest expense due to servicing the full year of new debt. We raised in part to fund the <unk> acquisition as well as other interest related increases in the current rising interest rate environment, and finally increased depreciation expense due to our significantly larger asset base, which is all.
So more heavily weighted in the U S.
The last piece of our guidance is the fully diluted share count as in the past years, we offer guidance on share count on a diluted weighted average basis, which is the number needed to compute our adjusted net income per share or adjusted EPS for.
For fiscal 'twenty, three we expect our share count to be in the range of 181 to 183 million shares.
Operator. This concludes our prepared remarks, and we would now like to open the call for questions.
Absolutely. Thank you.
Like to ask a question. Please press star followed by one on your telephone keypad.
Any reason you would like to remove that question. Please press star followed by team again to ask a question press Star one as a reminder.
New speaker phone, please remember to take up your handset before asking your question. Please.
Please limit your questions to one question and a follow up question and then re queue for any further questions.
Our next question comes from the line of stages <unk> with Morgan Stanley Davis. Your line is now open.
Hey, guys good morning.
So maybe just following up there Tom on your remarks on the margin headwinds.
Outside of that 300 to 400 bps FX hit on on both the top line as well as EBITDA can you share some color on the moving pieces here in terms of the facility remediation the new facility ramps and ample the contributions normalizing and I think you also called out some in.
Inflation dynamics. So if you can just share some color on how to build a bridge from where you finished fiscal 'twenty two and the midpoint of the guide next year on EBITDA margin that would be helpful.
Yeah sure. So thanks for the thanks for the question.
So your numbers are spot on in terms of FX, We did talk about FX impact of three to four points on the revenue and EBITDA, we do see a little bit more.
Of an impact to the to the bottom line from FX than we do it in the top line just given the geographic I would say mix.
Earnings there so.
I would say the EBITDA impact to FX is more towards the top of that range, where the where the.
The revenue impact I would say is more towards the low to the midpoint of that range. So figure somewhere between a half a basis point difference between between revenue and EBITDA there.
Other items and I did mentioned in my comments that we do have a remediation efforts continuing in Brussels.
Her into our fiscal 'twenty three of that obviously is.
Collected into our guidance for sure from.
From a COVID-19 standpoint, we mentioned in our prepared remarks that we have taking a two thirds haircut to the volumes we saw in fiscal 'twenty two in our fiscal 'twenty three guidance.
Further derisking from what was assumed.
As part of our May comment on our third quarter call.
Paul here and just given that decrease in volume and the absorption impact related to running at high levels of utilization on Covid.
Dedicated lines there is.
Relatively.
The impact of a relative impact to our overall margin profile as of as a result of that supply.
Our supply chain and inflationary pressures I would say continue.
To be a challenge and in some cases, even I would say more of a challenge now than they were in terms of how we've talked about this in the past we've seen more supply chain impact to our <unk> segment, specifically more recently around our ability to get our hands on active ingredients and other key inputs related to consumer health volumes so that.
We will play.
Roll into the a little bit of the margin story here and then just from an inflationary standpoint, I mean look just given the environment. We're in we're looking at impact related to wages that are probably about two times, what we would've seen in a normal year and that doesn't take into account.
What we're seeing on just the material side of things as well now, obviously, where we're able to pass those off to customers, where we're doing that we're going after price, where we can as well to help offset some of these pressures but.
Giving all of these moving pieces here to be sitting in a position on a constant currency basis, where we are seeing modest margin improvement is a pretty good position to be in and what I would consider the most.
Challenging macroeconomic environment I've seen in my career.
Lastly, I would just say we continue to be on track.
From a long term margin target year teach us, although we're not going to see the margin expansion of 100 plus basis points like we've seen over the last several years, we remain committed to our 28% EBITDA margin by sorry by 30% EBITA margin by fiscal 2026.
Got it that's Super helpful. Tom and then one for Alessandro just in terms of the impact of the new operating structure from a customer standpoint, what changes versus before any color. There on the commercial synergies that you alluded to and as you think about that.
The segment growth rates that you had pointed to embedded in your prior long term target, where do you expect to see the biggest uplift.
Sure sure look.
This is very simple in many ways, although not easy.
It required a little bit of organizational adjustments look way you look at the percentage of our customers, which are buying more than one service from Carbonite is a stellar.
Relatively low percentage and when you look at the web cast them that the schooling.
More and more customers, which have more on the small side the biotech type.
Type of customers that clearly they have the need of more than just one service out of covenant and that is an opportunity there to significantly increase the shadow of existing customers, which and the new customers will enjoy more than 100 service out of our covenant offering.
In the past our PS organization was creating some internal but he is from that with in the both the from a go to market strategy from an execution standpoint by combining all of these together can those but he has it been removed.
Our incentive plans, allowing people to benefit from a cross.
Offsetting the Windsor and we are already seeing good since the onset of these new organizations.
Some very good trends in these regards.
So with regards of the increased guidance for these segments look weak.
Need already investments.
In the dominate business, we have already said that the these gummy business is building.
Significantly above the average of the segment.
We also are expanding and resolved some bottleneck we have the capacity on the complex oral solid the business in North America, which would constraining your deposits a little bit our growth was assessed constrained, but we need that demand that we see demand and we couldnt. We couldnt really enjoyed the whole demanded that we were seeing there and lost.
The the fact that we have now both organically and Inorganically opening up our offering into high volt, which is the fastest growing.
Subsegment of oral solid primarily driven by the oncology pipeline all of that combined that really has an impact on the expected the growth rate.
All of these of these segments. So in many ways that these are these were things seem to making though over the last two years are locked up by visa new organization.
Got it very helpful. I appreciate the color.
Thank you for your question. Our next question comes from the line of Ms. <unk>.
Barclays Luc your line is now open.
Good morning, guys. Thanks for the question.
So jump in real quick here on the guide can you can you help frame us what your range of Covid is down there based on the guidance for 'twenty three so.
The midpoint is down two thirds on the volumes.
The worst case scenario would be in best case for you guys.
So look I would maybe just start here by saying I don't know that.
That there is a significant variation around COVID-19 volume to the low end here I would say the levels that we've taken COVID-19 volume down is reflective of contractual obligations.
We have with key customers.
Decreasing at two thirds from where we were in fiscal 'twenty, one puts it down to an hour.
Relatively.
A much smaller smaller level that it has been contributing in the past I would say.
That's not.
An assumption that I would say is really the very the variability here in.
In terms of the guidance range now if theres, obviously, if we see any any significant increases here.
Related to Covid demand that can factor into the high end or on the.
Outside of the high end of the range, but I wouldn't say that there is a material swing in the assumption around COVID-19 throughout the range of guidance I would say the real variability here in terms of our range is just a lot of the supply chain related challenges that we saw and are we going to have any difficulty in getting our hands on materials.
There as I mentioned, the midpoint of the range assumes that the macroeconomic environment. We're in today remained steady if that were to get worse that would be more of a.
A potential impact or to the to the to getting us towards the lower end of that range versus any further movement on the COVID-19 side, which as I said, we feel pretty good about around is.
Pretty much a firm outlook year.
Based on contractual obligations.
The other piece I would add look here.
During the spring that we have said many times that there was a still a number of variables as you can he began to significantly impact the potential outlook on closing <unk> seen demand in <unk>.
Those variables were primarily related to what is our second half of last fiscal year, meaning the first half of next calendar year. So.
Some of those variables.
Settled now.
And our creator planning.
Primarily with the <unk> holiday the vaccine.
I'm going to behave as from a seasonal standpoint, but we need that <unk> keeps that now we have a pretty good outlook that island of the seasonality of the of the vaccine and so forth and so we are in a better position to forecast in the second half of the of the our <unk> studio, which is the first six months of next year. So I believe that.
This is.
This is a solid outlook, we are providing today.
Alright, Great and then just a quick follow up on that so I mean, you guys are talking about.
Offsets coming from all of the capacity expansions that we've done in Bloomington, and Indianapolis and then the <unk>.
Suites coming on in Princeton and elsewhere can you just help us think about when there is the supply chains is there a particular indication that it's hitting hardest or is it just broad based and then can you give us a sense of how youre, how youre thinking about these easing.
Look when it comes to these at these new asset that these new assets, where is a combination of several assets which were.
Mensa to meet demand in a number of therapeutic areas, which we have seen over the last three years potentially in <unk>, but one of these.
Diabetes, which combines now.
There's some obesity as well.
The logic of these all of this.
And surely oncology.
The new the new approved to cell therapies.
Flip the oncology pipeline.
<unk> remarkable and that this is an area, where we see opportunity. So all of these assets were primarily built to meet the needs of these demand coming from these indications and therapeutic areas. Yes, I would just add to that look as I highlighted earlier in my comments too.
Tape outs.
Lot of the supply chain challenges that we've been seeing more recently have been impacting R.
Our Soc business and particularly on the consumer health side. So.
So not geared towards those large molecule biologic assets that that you were referencing yet.
Awesome great. Thank you.
Thank you for your question. Our next question comes from the line of Julia Qin with J P. Morgan Julia Your line is now open.
Hi, Good morning, Thanks for taking our question just a couple of to clear up the guidance.
So it's completely on time, you know activity.
Yes.
I'll take that and you and FX.
Alex maybe other non lacking.
Has there been any changes and in light of inflationary pressures.
How much packing computation.
Adam.
Sure. So so look I would say with the Derisking here from a guidance standpoint.
You broke up a little bit during the second part of your question Julia.
My best here to answer but in terms of the first part.
We did mention.
That we are seeing the base business here growing in excess of 25% in the fiscal year.
That's going to be a significant offset to the two thirds reduction in COVID-19 related volume that we have in our fiscal 'twenty three guidance.
That does contemplate growth across all of our technology offerings I would say from a biologic standpoint, we.
We are seeing X growth.
Ex COVID-19 growth on the drug product side.
But obviously cell and gene therapy is a significant contributor to the fiscal 'twenty three.
Both story.
A business that was not significantly impacted by COVID-19 related demand, our drug substance business out of both Madison and Bloomington, as well as capacity that we'll be bringing online in Europe as a result of the Oxford facility.
That was another business.
Obviously not.
Significantly impacted by Covid related demand that we will be seeing growth from.
In fiscal 'twenty three I think there may have been a part of your questions around Covid therapeutics and here I would say Covid therapeutics are not a significant growth driver as we've talked about the bulk of our COVID-19 related revenue has been from for more vaccine.
Related revenue and in terms of.
I think the second part of your question was related to supply chain challenges and what the impact.
There is and I think we've talked about that already mostly impacting the consumer health side of the business in terms of inflationary pressures.
We are seeing wages up two times to what they would be in a normal year as well as seeing increases for many suppliers on the vendor side and then we're looking to be active in terms of being able to recoup that.
Through through our customers, where our contracts give us the ability to as well as I would say driving off cycle price increases, where we're able to from.
From customers to to ease that impact, but again, despite all of those challenges we are looking at modest margin expansion at.
At the midpoint of our fiscal 'twenty three guidance on a constant currency basis.
Okay. Thanks.
<unk>.
Long term guidance youre, raising the high end of that.
Sure.
On the PC.
And our revenue synergy can you talk about how long do you think it would take for you to achieve their full potential and question. We're at the high end of that 10% growth and then on the biologic side has there been any improved.
Outlook on that side, given what's happening on a new modality and around the biosimilar.
<unk> the midpoint at that 10% 15%.
Sure look strictly we don't we don't give a very short term indications of guidance by by single segment, but in terms of the Anthony <unk> broadly to your question.
We're already seeing.
<unk> of that segment.
Accelerating towards the new growth that we have projected.
As I have said that these are <unk>.
If you look at the factors that I need to mention which are behind that acceleration.
Some of them a little already in.
In play in the last couple of years right. So with the addition of the gummy business.
We will be completely organic or <unk>. There is only one quarter. What he is going to be inorganic. So not only we have a full ownership of the assets, but we are very much accelerating on expanding capacity to meet.
The high demand in that area.
Our expansions and acceleration on complex oral solid in North America as well as been has been quite quite executed well by the team and these coming available for executing on programs for which we have secured over the last few years.
And I would say in general that there is a continued to rebound to our consumer product with specific job of Coca Cola categories.
And so im pain relief, we choose which is another area, where we are seeing significant demand if anything there we're trying to overcome some supply challenges and so when you look at the all of these dynamics, which I didn't mention is that the dynamics that have been in.
In play already in the last few quarters.
To fruition.
On top of that we are confident that the.
Accelerating.
Commercial synergies that we are going to enable with the new organization will allow us to further accelerate this growth.
Next question operator.
Thank you. Our next question comes from the line of Jacob Johnson with Stephens Jacob Your line is now open.
Hey, good morning.
Maybe starting off with just a higher level question.
$2 5 billion I think of biologics revenue in FY 'twenty. Two you have got the BWI expansion Master cell Princeton, Oxford.
And Bloomington number of capacity additions there I know capacity is hard to define or quantify but can you just talk about the amount of capacity you've added to your biologics segment over the last couple of years.
What that could mean for growth as we look out the next several years.
Yes, sure look as you pointed out is quite a remarkable the capacity that we have added.
The remaining debt execution that we're going to do what I can tell you is that the bi are continuing on that execution in the plans we have.
In the last in the next 18 months 18 to 24 months, we are very well position to deliver our fiscal 2006.
Targets, if you like so in many ways that we have already created a significant amount of the capacity that once the getting to utilize that we believe at the <unk>.
Target. So probably this is giving you a little bit of a quantitative.
Measure of the capacity being created.
Another way to look at that look when it comes to Doc product that we've been primarily focusing complementing the offsetting <unk> on top of vials.
And when it comes to <unk>. So it would be in the just doing expansion and densify our production our production schedule and when it comes to <unk>.
Gene therapies would be essentially going to throw in the 10 suites to athene suites.
In BWI. So these again gives you a little bit.
Of a measure of what is the potential of this capacity going forward.
Got it thanks for that Alexandra and then just one on the Covid kind of roll off can you just talked about how quickly you can transition.
The drug product assets to new kind of non COVID-19 applications is there any lag period or downtime associated with switching those lines over and maybe how should we think about the timing of that transition throughout 2023 is that something where maybe there could be a little softness early in the year.
As youre transitioning or.
Not so much.
Look the transition needs is mostly seamless meaning that these opening in parallel one thing to that.
It is happening is that mostly the lines in which we have plant city, new put all of that so we've been just sitting and onboarding of new programs are lines, which were built in parallel of the coffee lines. We always wanted to have the possibility to serve new customers and new programs was still leaving enough capacity.
To satisfy the coffee the vaccine demand, which in many ways is steel.
Totally predictable, although we're now getting to a much better visibility on on <unk>. So I would tell you that that the transition has been a pretty seamless you don't have to think about these alike has stopped in vaccine and starting something new but.
Mostly things that are happening in different formats and different.
Production lines.
With regards of some of the ones that that in fact, they are going to be served out of the car.
The coffee.
Vaccine lines, which are going to demand.
The entirety of the current vaccine supplies made in vials.
Some of these programs.
To a large extent, we can onboard them in but it did them on the line that was still making the vaccine so.
It's a kind of a <unk> type of dynamic as opposed to having a gap in between.
Got it thanks for taking questions.
Thank you for your question. Our next question comes from the line of Derik de Bruin with Bank of America Garik. Your line is now open.
Hi, good morning, and thank you for taking my questions. So I've got a few which I'm just going to shoot off here.
One what's the embedded organic revenue growth guide by segment for the biologic and PCH.
The first one the second one is going to be.
When you talk about a two thirds volume reduction for.
You are covered vaccines are you also implying that two thirds revenue.
Sumit you have some take or pay contracts and then the third one is.
You talked about a 28% adjusted EBITDA margin.
For 2024 is that still something that I mean, I realize you're back in your <unk>.
30% number by 2026, just wondering if that 28% number is that's how we should sort of think about the rebound for next year. Thank you.
So I'll start here I'll sound or feel free to jump in so I'll start with your last question first Eric outlook and we're not in a position at this point to give guidance around fiscal 'twenty four and I think there's still a lot to understand in terms of what the macro environment looks like today, and what that where that heads over the next year, what I. What I have said is we're absolutely on track.
<unk> continued with confident about our ability to deliver on the 30%.
EBITDA margin target for for fiscal 2026.
In terms of the organic revenue growth on a segment by segment basis I would tell you that that's not something we've talked about here specifically, we did make comments in our prepared remarks that we're seeing 25%.
<unk>, 25% growth.
Across our business.
Excluding COVID-19 demand I think you can do some math and come come based on the disclosures. We've made here as well as based on customer concentration related disclosure that will be in our 10-K and be able to estimate.
Tight band.
The Covid related impact is here and I would say as you.
As you take that into consideration, it's very difficult to have two thirds.
Related volume headwind on Covid and be able to see growth within biologics, including that in the 10% to 15% range. So I think you can maybe take from that.
Where we are there.
From a.
So.
OSD basis will obviously be reporting those out as a farmer incomes.
In consumer health segment, starting in next quarter.
That is a business that is growing outside of here in 2023 guidance that 6% to 10% long term outlook here, obviously, considering we're seeing 25% growth across the business on the next cohort basis, Yes. So look with regards of your question around that type of pace.
And that kind of a routine question over the last few years, a few months I've got a date to date, which I've already shared the while we feel strong about our peak will be <unk>.
<unk> and so on we're also very mindful of being partners with our great clients and making sure that released into the needs and we try to find.
We win.
Solution for.
And landscape that.
He is very ought to read that for everyone.
So in.
In many ways the breadth of the offering of Covenant gives us optionality in sometimes two to trade that some of the what is due to volume Cds.
Contracts with something else that I believe that.
Part of the success, we're having in non coffee business, which is growing at more than 25% is also due to these approach which have been very very successful in securing.
And the good outlook on non coffee.
Coffee business.
Leveraging those relationships and our partnership approach.
So we feel pretty good about our approach. So far we believe has created momentum in non coffee business and despite the lar is possibly behind our confidence in the long term prospects of the company.
Thank you.
Thank you for your question. Our next question comes from the line of Jack Meehan with Nephron Research Jack Your line is now open.
Thank you good morning.
Wanted to kind of continue along that line of questioning as it pertains to the guide.
Is there any help you can provide around seasonality you talked about some of the seasonality in the business. This year just to help with pacing in terms, maybe expectations, especially anything for the first quarter it would be helpful.
Yes look Jack we're going to fall short of giving specific quarterly guidance here, but let me just give you some directional commentary I would say as we we.
We did make a point here to reference.
Seasonality that we see in this business and I would say what we're seeing in fiscal 'twenty, two probably feels a little bit more like what we've seen in fiscal 'twenty and prior to that given that fiscal <unk> I'm sorry.
Turning to fiscal 'twenty, three now feeling more like fiscal 'twenty, one and fiscal 'twenty from a seasonality perspective more so than what we saw fiscal 'twenty, two which was obviously a year that was <unk>.
Significantly skewed by by Covid related increases through sequential quarters until we got to a fourth quarter, where the volume.
Declines here.
We did mention about 60% of our absolute dollar EBITDA being generated in the second half of the fiscal year being 40% of that for the first half of the fiscal year and I would say in terms of the quarterly phasing again going back to what Q1 Q2 splits looked like in that.
And that $19 2021 time period is probably a close proxy to how you can see the year play out from a quarterly phasing standpoint in 'twenty three.
Alright, that's helpful and then on metrics. So you disclosed the over $90 million of trailing sales.
The supply agreement, what's the annualized revenue contribution we should expect upon close.
So we will give more specifics around the guidance here of metrics when we when we do close the transaction, which we're hoping to do by the end of the calendar year here.
Did talk about growth rates that we expect to see from that business being.
Very closely aligned to that of what the new farmer consumer health business of 6% to 10% would look like.
And you can use that $90 million as a base knowing that obviously this will only be a partial year contribution that we would see in fiscal 'twenty, three and again that exactly how much will depend on the timing of the close of the transaction. So we will give some more specifics around the.
The revenue and EBITDA contribution for fiscal 'twenty three once that deal closes in the first call post close I would just add one comment more general one reason why we like the fee. So prescription oral solid is that you normally have a pretty good visibility on the revenue so for a fairly good arise on the given the.
Prescription nature of the business and the strength of the pipeline.
Next question operator.
Our next question comes from the line of Paul Knight with Keybanc.
Your line is now open.
Hi, Alexandra Thanks for the question.
Where are you in the go to market strategy are you halfway there and the productivity you expect could you give us some metrics around where we are today with.
This strategy.
Sure.
Great question I believe.
Pretty good place.
I believe look.
<unk> been always very happy about our sales machine, which has been producing consistent organic growth over the last four five years I would say.
Here is.
Is it more in terms of <unk>.
And making sure that when that when the one off sales rep engagement.
With a customer and we do a validation for the customer we speak of the full advantage of the relationship and try to offer.
More than just one services. So I would say that look I cannot point to trust with either percentage of completion of the plan, but we are pretty advanced.
What we are trying to implement here.
Our basic foundation, so while our sales machine remain a very very strong and what drove it.
<unk> success in the last few years.
And he said this is the way you need to see is not that evolution, but the <unk> the go to market.
Strategy, so that we can unlock value with the value was blocked by our internal barriers.
And you raised your long term growth guidance by 200 basis points is that due to your increased optimism around.
Around a single dose still finish outlook or is it that plus cell therapy. What are the components of that 200 basis point increase are the big drivers I think is the best way to ask that yes.
Yeah sure look.
I believe that on the biologics side, our outlook remains pretty much.
The same that was before that's really not what is driving this increase we remain very bullish on the biologic story at the 10% to 15% what is driving deal with all of the increase in the growth expectation from the company is if you like.
The assets, which were a little bit.
Behind in the growth story of the company are dragging down the overall growth rate perspective for the company, which were more in the small molecule side and the <unk>.
The small molecule footprint, we were able to implement that through the pandemic, which went a little bit under the radar I understand that.
During the <unk> I mean, it was making the use was related to biologics vaccines and so on but we were working very very hard.
In the background, but in addressing some of the gaps that we had in the small molecule portfolio to enable faster growth there and I will point out again, primarily in the consumer <unk>.
Getting on top of these.
In <unk> the dosage form of <unk>, which is again is a significant contributor to that acceleration. The fact that we've been investing organically in our Kentucky facility.
Our Florida for CBD, which are setting the complex oral solid market in the United States, which is very very healthy at this point in time as well as leveraging some of the dynamics in the consumer that is deducted an initial period of.
If you'd like to prices at the beginning of the pandemic came back of particularly strong so is <unk>.
The PCH side that you need to see the increase.
We have increased 200 basis points.
The top end on the PCH side compared to the past and this is really what is driving our most.
More comfortable outlook about the company and and really putting us in a comfortable position to raise our long term guidance for the organization.
Thank you.
Thank you for your question. Our next question comes from the line of Dave Windley with Jefferies.
Dave Your line is now open.
Hi, Thanks, Good morning, I have a couple of clarifications and then a more strategic question. So.
Am I right in calculating that the diabetes related royalties in the quarter would be about maybe $10 million is done a fair estimate.
David we haven't disclosed exactly.
What the contribution was there we did point to the fact that it was a significant driver of the margin profile. So I think.
We were able to do that math and triangulate something in that range I think thats directional.
Yes, okay.
And secondly on Tom you talked about lower.
Component sourcing with Covid, but then on the other hand.
Lower absorption from from lower Covid volumes, I guess I'm wondering.
If kind of the bottom line margin impact.
From the lower Covid assumptions in 'twenty, three is margin dilutive or margin accretive taking those two impacts together.
Yes look I think it's I think youre right. We did mentioned both here, we mentioned that with the declining COVID-19 related revenue that we will see the component sourcing dynamics start to start to normalize here in the year and then obviously in talking about some of the margin pressure opportunities.
Here, we talked about.
The.
We've talked about the.
The absorption related item driven volumes I would take the.
The point of referencing the component sourcing piece is really more material for the biologics segment that I would say it is for the company overall.
Meanwhile, the absorption piece does have a more meaningful impact on the company overall here, Dave just given the fact that we're talking about.
Dedicated capacity that was running at very high levels of utilization.
And being replaced whether on the same asset and other assets that we brought online during that period here.
Not quantifying each of those for you, but I would say they essentially offset each other but there's probably a little bit more impact to the bottom line here from an absorption standpoint, just as we start to ramp up other assets.
That we brought online during the Covid pandemic that are I would say slow on the uptake Youre right you don't plug into new syringe line and be operating at $85, 90% utilization and start to see that full absorption right Theres a theres a theres a ramp up period here that we see that takes into consideration, but I would say.
The fact that we're in again in a position where we are seeing modest margin expansion. Despite a lot of these moving pieces and challenging macroeconomic environment.
Is something we're pleased with and we're obviously going to look to maximize the margin expansion opportunity that we have here in fiscal 'twenty three on our path towards the 30% by fiscal 'twenty six.
As a follow up.
Comment on these.
I would tell you.
Clearly as the vaccine for <unk>, the transition from pandemic and Danica use they will resemble a little bit more the thought that in all of the other vaccines, which means that you're going to produce a significant amount of volumes.
Shelf the timeframe and the rest of the year you would essentially in a much lower production mode. So that is a little bit more challenging to manage it from.
Absorption and profitability standpoint.
Something that takes some time to organize yourself for.
And that's why I believe we have a very good plan that we are discussing these also with our partners, but that is a dynamic that needs to be taken into account as you move from the pandemic.
Centrally running flat out through the 12 months.
Moving to a more traditional vaccine manufacturing that we chose that that challenge always Ed will always have.
So the last question I wanted to ask is around your long term growth of the raised guidance. There. So 'twenty three we will start up I don't know if we want to think about a.
Four year periods since you do have 26 targets.
In the public maybe a four year period is a reasonable period to think about youre, starting that four year period, a couple of points lower than the long term guide should we think about this as a kind of a midpoint, 10% CAGR target where at some point over that horizon, you'll grow faster than the 10% or do you think of it is.
Getting to 10% after fiscal 'twenty three.
Thanks.
So look clearly Cds that.
Fiscal year 'twenty to be a little bit there is a transition year from a strategic standpoint.
It's multiple the fact that.
We are reducing two thirds, our expectation from Covid vaccines and at the same time, we we are.
In line.
With the expectations and I would point you towards.
No.
What we shared the down but the non coffee business and defense there right. So we have highlighted that the debt above 25% I believe you guys can make some months and be a little bit more accurate on that we've provided.
Our mission to be to do so but that debt extending out that all the moves we've done recession and retooling that portfolio on the remaining business with us.
In a very strong position as we transition that outside the pandemic.
Thank you that's great alright.
Thanks, Steve next question please.
Thank you for your question as a brief reminder to give everyone a chance to ask a question. Please limit your question T. J S. Whang. Thank you our next.
Question comes from the line of Kristine <unk> with William Blair Christine Your line is open.
Hi, yes. Thanks for the question just one for me so.
Noted a slowdown in SBA approvals in the first half of the year.
Over last year any insight into the dynamics playing out here and do you see this as having any near term impact on catalyst business. Thanks.
Well look from our perspective, we've been pretty pleased with we get approvals that have been impacting our pipeline.
And we.
We see further opportunities going forward, so look it's a little bit.
Not necessarily the macro dynamic of the approvals that evidence out there significantly.
In fact, Scott 90 defense.
It's very discreet write them very very much focused on some products, but I cannot tell you we've been seeing some good success of the products in our pipeline in the last few quarters.
Thank you.
Thank you for your question. Our next question comes from the line of Jon <unk> with UBS. John Your line is now open.
And it looks like lease lines connection with John Our next question comes from the line of Justin Bowers.
Deutsche Bank Justin Your line is now open.
Thank you and good morning, I'll keep it.
Jiffy.
Collyn long, but just in terms of the new capacity, specifically UK in Princeton.
When when does that really start coming online and the fiscal year and then.
By year end.
What.
The percentage of the past will be built out with respect to.
The footprint of those facilities.
Sure so.
Very different answers for the two facilities. So when he got the greenstone commercial cell therapy capacity is mostly already online and in fact that is already one product which is in late stage running there.
We've seen very very strong interest out of the gate after we announce that.
And.
It's more related to the time for us to board with these programs into capacity. So the constraining factor increased earnings is really around our ability to close these deals in both of these tech transfers and these activities into <unk>, which again I remember everybody you skewed more towards late stage. So we're talking about mature sales data.
Programs, which have which are trying to find home for their commercial phase III less commercial needs. So that's brings to them.
Cell therapy, serving mostly oncology therapies we.
With regards of Oxford is a little bit of a different story. The buildout is proceeding at pace I believe that we are very close to open our PD side of the house, where we're going to start working on on the if you like of the Scaleup of visa cell lines that these this facility will be mostly serving.
Messenger RNA and proteins to large extent and and then the largest scale of biologics that will come a little bit later in the year. We expect that these these assets such as many of these revenues as we said in the last part of the fiscal year.
We believe that <unk> is going to be a little bit faster than that yes, and I'll just add just to that.
Related to Oxford, specifically this was a pivot for US here in terms of building out capacity for European drug substance originally in our <unk> facility and then we were able to accelerate that with the acquisition of Oxford. So our original drug substance plans didn't have revenue contribution until probably midway through.
Our fiscal 2000 and for years, if not later and as Alessandro said as a result of this acceleration through what we have.
What we acquired as well as the capacity we are deploying in that site, we would be in a position to be able to see revenue contributions late in fiscal 'twenty three.
Yes, that's a great point in time, okay. Thanks, that's it for me.
Thank you for your question. Our next question comes from the line of John Caribbean with UBS. John Your line is now open.
Hi can you guys hear me now.
Yes.
Thanks for taking my question just one for me can you just talk a little bit more on the M&A outlook I guess, how are you seeing the valuations tracking and then after the metric transaction do you see potential for additional activity in 2023 and any areas within the biologic portfolio that could present inorganic opportunities.
Thanks.
So look.
I believe that.
The first before the summer, we didn't see significant moves and devaluations.
And so forth.
The space will still waiting to factually, the new reality of multiples into the into the assets.
I believe we yes, we are starting to see some early signs of a more.
Catching up with the current environment, especially when it comes to cost of capital and macroeconomic uncertainty of the next.
A couple of years as well as.
Biotech funding so.
I believe that.
As we move in the next few quarters I do I do expect some some correction that I will add though that the premium assets in a speed of steel.
Kind of expensive because they.
<unk>.
Pretty good the strategic prospect in front of them. So I believe is a little bit of a mixed Becker I would tell you that of course multiple chemical Institute.
But for gathering is probably never all the undervaluation of multiple and primarily our financial evolution as more of a strategic evaluation and how are we going to make sure that when we add an asset to <unk>.
Covenant, we can accelerate growth and generate the synergies.
All of these in the not only enable more growth out of covenant, but we can also accelerate the growth into into these assets. This is what we believe are four metrics that we believe that by insisting these opinion lots with an hour.
Much larger of a commercial engine.
To accelerate the pipeline creation and tech transfer on the other day and we expect that.
These offsetting this completing these all fitting in downstream high potent capacity will create additional opportunities for some of our assets, which have more early stage, which you didn't have a necessarily a downstream.
Paucity prior so <unk> is squarely in the definition of that in terms of M&A Covenant is always heading up <unk>.
Folio of M&A opportunities as we explore the market and whenever we see an opportunity to accelerate.
Accelerated growth and expand margins through.
What I just described we definitely are interested in exploring that opportunity.
Thanks for taking the question.
Thank you for your question. Our next question comes from the line of Sean Dodge with RBC capital markets. Sean Your line is now open.
Yes, thanks, good morning.
On the organizational changes I almost wonder you mentioned.
The revenue synergies from that how should we think about the cost impact is realigning. The commercial organization is that something you need to invest or add head count view.
Or do you think there is some some cost efficiencies that you can can drive longer term along with those I guess the revenue growth in Hinton are they also are intended to be margin percentage enhancing.
Sure look as I said on the commercial side most of the foundations were already there we needed to tweak a little bit our our incentive plans and so forth to make sure that we drive the right behaviors that you moved some artificial P&L internal body, which ware and not <unk>.
In answering our opportunities to sell across.
Our portfolio of offerings to our customers, which by the way, we'll buy them anyway, either for module from others, so whether they buy all of them from us.
So on that side I don't believe that there will be any any cost impact on the commercial side of the house, we did points towards that the diesel organization is a little bit leaner in terms of management and shouldn't be enables us to drive operational excellence across the board more effectively that we used to do before.
Shedding some best practice essentially of all.
I didn't get some of the obligation when you think about what he's done.
Managing a program, which is both that giving the customer formulation development clinical material and at the same time distributing the clinical trials for their own trials because there is some synergies there in the way you manage these projects close while before you have to manage the different PTC slightly Seth when you factor yet.
The defense licenses, which as I said was not desk homeowners could have been so clearly in that regards we see an opportunity here to continue to drive operational excellence and efficiency and lean approach. So bottom line is that yes, we do expect that visa decent not only to drive.
Accelerated topline growth, but also provide us a little bit of productivity and efficiency and I would just add Shaun this gives us even more confidence than we already had around being able to achieve.
Our fiscal 'twenty six long term EBITDA margin target of 30%.
Okay.
Thank you.
Thank you for your question. Our final question comes from the line of Evan Zhou barely.
And then your line is now.
Hey, Thanks I appreciate it just one from me, obviously I wanted to relate in the long range Capex outlook.
Outlook to your updated long range kind of revenue growth plan today.
We're at the point, where we've doubled the revenue growth goals since the IPO can.
Can you talk about how that would relate to capex. After we get past kind of the bolus of projects.
That's elevating the number higher here, what that equates to a longer run percent of your revenue spent on capex, because you're kind of getting to the point on your long range revenue plan, where it feels like some of this higher capex is structural rather than transitory. So anything you can provide on a longer range settling of that number would be helpful.
So I will let Tom to provide some more color around the high should think about it what I can tell you is that the fact that the now these overall organic growth.
Spectation ease is accelerated by the PCA segment as opposed to the Biologics segment. These good news in that regard because our PTA segment.
He's a significantly lower in terms of capital intensity towards biologics and again that was very very intentional from either we need to organize that our biologics segment is very capital intensive specific setting when it comes to us it's like a protein type product.
Gene therapies, and so forth, but when you look at the complex oral solid the way you look at the gummies. So when you look at the Softgel. So when you look at it.
Early stage formulation development assets and so forth. These are assets, we come in with a lower capital intensity as a percentage of revenue. So as we accelerate that growth and that path to continue to have a significant share of the portfolio of Carbonite. Overall. This is good news in terms of <unk>.
That intensity of the organization with specific of Biologics I will let it's almost to respond yes, I think it's a great point Evan.
Think.
We historically have been spending capital at a clip of somewhere between 8% to 10% we were at that time somewhere between four and 6% grower maybe four 8%.
Tops and with the capital that we've deployed over the last couple of years into.
<unk> I think it's been pointed out to me that many of our peers that are more heavily biologics weighted than we are spending something like 20% to 25% of revenue.
Look I think Alexandra points here around what we're seeing on the pharma and consumer health side of the business being less capital intensive, but yet seeing the growth is as accurate. This year, we've talked about spending something in that.
13% to 15% of range.
I don't think that a normal year for us is 8% to 10% any longer given the mix shift of assets. We now have in the portfolio. It feels like the normal for US now just given how much maintenance, we have across 50, plus rooftop feels more like about 10%.
So we do need to get back down to that 10% I don't know that we get there exactly next year, but we'll obviously give some more specifics around how this phases out, but I would expect 13% to 15%. This year, probably a step down from that level next year, probably not quite to the to the 10% normal run rate, but then.
Thereafter, or are we getting close to if not at that 10% and and that being a new sort of base capex level of deployment to expect.
I appreciate it thank you.
Thank you for your question. This concludes our Q&A session for today's call I will now pass the call back to Alessandro Maselli for any closing remarks. Thank you.
Thank you everyone for taking the time to join our call and your continued support of Covenant. We were pleased to deliver record results in fiscal 'twenty, two and we are fully committed to deliver another strong year in fiscal 'twenty three and beyond thank you.
This concludes today's conference call. Thank you for your participation you may now disconnect your line.